Medicines safeguard clause: single contribution based on a revenue amount M
The 2019 Social Security Financing Act reformed the safeguard clause paid by pharmaceutical companies. The two separate trigger rates for community and hospital care (Lv and Lh rates) are replaced by a single contribution, due when revenue from reimbursable medicines, net of agreed rebates, exceeds an amount M set in value terms. For 2019, M equals 1.005 times the revenue achieved in 2018.
Measure originators
No official estimate found for this measure.
Measure impact
Laboratories whose sales of reimbursed medicines grow beyond the threshold pay a contribution to the health insurance fund, unless they have signed a rebate agreement with the Economic Committee for Health Products. The mechanism aims to keep medicine spending within the national health expenditure target.
Official references
Sources
Procedure timeline
Follow the progress of this fiscal measure through the different stages of the parliamentary procedure.
Administrative implementation
Entrée en vigueur de la mesure et mise en œuvre par l'administration
President of the Republic signature
Publication au Journal officiel
Possible referral to Constitutional Council
Décision de conformité / censure partielle